AstraZeneca and Daiichi Sankyo’s drug, Enhertu, has been approved by the European Union for treatment of adult patients with an aggressive form of breast cancer.
AstraZeneca said on Tuesday Enhertu could be used as a monotherapy in cases with unresectable or metastatic HER2-positive breast cancer.
The treatment was jointly developed and commercialised by AstraZeneca and Daiichi Sankyo. The European Medicines Agency (EMA) gave its endorsement late in June.
The EMA said Enhertu was effective at shrinking the tumour in patients with metastatic breast cancer or breast cancer that could not be removed by surgery.
We have recently deactivated our website’s comment provider in favour of other channels of distribution and commentary. We encourage you to join the conversation on our stories via our Facebook, Twitter and other social media pages.